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Abstract
Background: Clinical surveillance may have underestimated the real extent of the spread of the new strain of influenza A/
H1N1, which surfaced in April 2009 originating the first influenza pandemic of the 21
st century. Here we report a serological
investigation on an influenza A/H1N1pdm outbreak in an Italian military ship while cruising in the Mediterranean Sea (May
24-September 6, 2009).
Methods: The contemporary presence of HAI and CF antibodies was used to retrospectively estimate the extent of influenza
A/H1N1pdm spread across the crew members (median age: 29 years).
Findings: Duringthe cruise,2crewmembersfulfilledthesurveillancecasedefinitionforinfluenza,butonly onewaslaboratory
confirmed by influenza A/H1N1pdm-specific RT-PCR; 52 reported acute respiratory illness (ARI) episodes, and 183 reported no
ARI episodes. Overall, among the 211 crew member for whom a valid serological result was available, 39.3% tested
seropositive for influenza A/H1N1pdm. The proportion of seropositives was significantly associated with more crowded living
quartersandtendedtobehigher inthoseaged,40andinthosereportingARIorsuspected/confirmedinfluenzaA/H1N1pdm
compared to the asymptomatic individuals. No association was found with previous seasonal influenza vaccination.
Conclusions: These findings underline the risk for rapid spread of novel strains of influenza A in confined environment, such
as military ships, where crowding, rigorous working environment, physiologic stress occur. The high proportion of
asymptomatic infections in this ship-borne outbreak supports the concept that serological surveillance in such semi-closed
communities is essential to appreciate the real extent of influenza A/H1N1pdm spread and can constitute, since the early
stage of a pandemic, an useful model to predict the public health impact of pandemic influenza and to establish
proportionate and effective countermeasures.
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Introduction
During April-May 2009, a new strain of influenza A rapidly
spreading from Mexico all around the world, originated the first
influenza pandemic of the 21
st century. Early data from Mexico
suggested that this new pandemic virus strain (A/H1N1pdm) had
a high infection rate in younger age groups, and high case-fatality
ratio, at least in some particular risk groups [1–3].
However, most of these inferences derived from confirmed cases
that rely on laboratory results showing the presence of influenza
virus genome in the respiratory tract of the affected individuals,
selected on the basis of a strict case definition that tended to exclude
less severe cases.
Subsequent reports suggested that the actual burden of the
infectionhadbeen largelyunderestimated,whiletheclinicalseverity
has been overestimated, and that serological investigation may be
helpful to establish a more accurate estimate of the infection rate,
especially since a substantial proportion of influenza infections are
asymptomatic [4]. In fact, mild afebrile illness has been described in
8 to 32% of infected persons [5]. Consistently, seroincidence has
been reported to be 10 times higher than estimates from clinical
surveillance [6–7], and a high proportion (36%) of A/H1N1pdm
seroconverters areasymptomatic,similarlytoseasonalinfluenza[8].
In keeping with these observations, estimates of the secondary
attack rate have shown wide variability, depending on the methods
used. For instance, estimates of secondary attack rate among
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15933household contacts reported in different studies ranged from 4% to
36%, with lower figures when estimated through PCR confirma-
tion of clinically apparent disease and higher figures when
estimated through retrospective serology [1, 8–9].
Some studies have been conducted on the crew members of
military ships that represent a particular semi-closed community
of individuals with rather homogeneous demographic character-
istics. From these reports, 7.3%–12% shipmates have contracted
the pandemic influenza on the basis of symptoms (ILI) [10–12].
In the studies from Almond and from Crum-Cianflone the rate of
infection was lower (respectively 3.13% and 8%) if estimated
through PCR [10–11]. A substantially higher proportion of
infections, was reported for another shipborne outbreak, where
22% of shipmates acquired the infection (symptomatic, PCR-
positive) in a Peruvian Navy ship docked at San Francisco during
June 2009 [13]. From these studies, it was not possible to estimate
the real extent of the outbreaks, as the starting criterion for case
definition was the presence of ILI, therefore both afebrile
respiratory illnesses and asymptomatic infections have been
disregarded. In fact, based on seroconversion rate, a study
conducted in military personnel from Singapore estimated an
infection rate of 29.4% [14].
Here we report a retrospective serological investigation on the
crew members of a military ship that left Italy on May 24, 2009 and
stopped at several Mediterranean ports before ending the cruise.
During the cruise, several cases of acute respiratory illnesses (ARI)
occurred, but only 2 met the ILI case definition. Laboratory
confirmation of influenza A/H1N1pdm infection was carried out at
the closest harbour hospital only in these 2 patients, resulting in one
confirmed case. Both cases were kept in isolation in this hospital,
until the resolution of symptoms. Considering the reported range of
the attack rate for influenza [10–15], the number of cases fulfilling
the case definition of ILI seemed to be rather low, and, in addition,
it was surprising that in a quasi-closed community only one case of
confirmed A/H1N1pdm infection occurred during the cruise
timeline. Therefore, once the ship was on the way back to Italy, it
was decided to carry out a serological survey to try to estimate the
real extent of the outbreak among crew members.
Results
Description of the shipborn outbreak
Scirocco, an Italian military ship, sailed from Taranto (Italy) on
May 24, 2009. The ship had a crew of 237 members (93.2% men)
with a median age of 29 years (interquartile range 26–35 years).
One hundred and twenty nine (54.4%) crewmembers had been
vaccinated against seasonal influenza during the 2008–2009 season.
Soon after the departure, following the alarm launched by Italy to
the Ministry of Health, surveillance of A/H1N1pdm influenza was
instituted on the ship and crewmen were encouraged to report to
infirmary any acute onset of respiratory symptoms. For the purpose
of surveillance, a case of suspected A/H1N1pdm was defined as
fever $38uC plus one or more respiratory symptoms (cough, sore
throat, rhinorrhea) and one or more general symptoms (limb/joint
pain, headache, malaise), according to the case definition in use in
Italy at that time (http://www.normativasanitaria.it/normasan-
pdf/0000/29528_1.pdf). Respiratory illnesses, which did not fulfill
the case definition, were classified as acute respiratory illness (ARI).
The ship reached Beirut, Lebanon, on May 27, 2009 and
stopped there for 3 days. The ship continued her cruise in the
Mediterranean Sea with six three-day stops in Beirut between June
22 and August 31. The ship also stopped in Lymassol, Cyprus on
June 8 to 10, 2009, and in Mersin Turkey, July 1 to 6, 2009. When
the ship was at moorings, crewmen were allowed to go ashore for
protocol or visiting activities, on a rotational basis (one-third
remaining on board).
At the time the ship left Italy, there were 19 laboratory-
confirmed A/H1N1pdm influenza cases reported in Italy (data
available from Italian Ministry of Health http://www.sanita.it/
Malinf_gestione/Rischi/documenti/137-09.pdf). A/H1N1pdm
influenza cases were also reported in Lebanon (n=3) (data
available from WHO http://www.who.int/csr/don/2009_06_03
/en/index.html), Cyprus (n=1) (data available from WHO
http://www.who.int/csr/don/2009_06_10a/en/index.html) and
Turkey (n=40) (data available from WHO http://www.who.int/
csr/don/2009_07_03/en/index.html) at the time the ship docked
there for the first time.
On August 9, 2009 (week 32) a crewmember presented to
infirmary reporting fever (.38uC), malaise and rhinorrhea. A
rapid influenza A+B test was performed (Quickvue, Quidel, CA,
USA) which resulted positive, and the seaman was started on
Oseltamivir (TAMIFLU 75 mg, 2 tablets/die). The next day the
patient was admitted to the infectious disease unit at Rafik Hariri
University Hospital in Beirut, were a pharyngeal swab resulted
positive to influenza A A/H1N1pdm by the RT-PCR [16]. The
patient was kept in isolation at Hariri Hospital until August 17
when he was discharged and returned to the ship.
Another crewmember, who had presented with rhinorrea and
malaise on August 8 (week 32), 2009, developed fever (.38uC) on
August 11, fulfilling the suspected case definition. Thus a rapid
influenza A+B test was performed which resulted positive. He was
started on Oseltamivir and was admitted to Hariri hospital. A
pharyngeal swab was negative for influenza A A/H1N1pdm by
RT-PCR. The patient was discharged from the hospital on August
17 and returned to the ship.
No other cases fulfilling the case definition for suspected A/
H1N1pdm influenza were recorded during the cruise duration
(from May 24, week 21, to September 6, week 36). However 59
additional episodes of ARI occurred in 52 crew members after the
ship departure. None of these cases was tested for the presence of
influenza A/H1N1pdm virus in respiratory secretions. The
distribution of ARI and suspected or confirmed cases according
to the time of symptoms onset is shown in Figure 1. During the
first 4 weeks of the cruise 1 or 2 ARI cases per week were
recorded. The number of cases increased thereafter, to reach 8
and 9 cases per week at weeks 31 and 36, respectively.
Establishment of serological cut offs and estimate of
seroprevalence in the civilian population matching the
personal data of military shipmates
Since pre-outbreak serum samples of ship military personnel
were not available, our estimate of the infection rate must be solely
based on the presence of antibodies at the end of the cruise. To
establish an appropriate criterion to retrospectively diagnose A/
H1N1pdm infection, we used paired acute and convalescent
serum samples from patients with A/H1N1pdm infection
confirmed by RT-PCR (group 1) taken #4 days post-symptom
onset (T0) and 2 or 3 weeks later (T1). In addition, to obtain data
on the pre-pandemic prevalence of antibodies to A/H1N1pdm,
we used residual serum samples, stored in the local biorepository,
that had been submitted to our laboratory for HIV antibody
screening and resulted HIV-negative in September 2008, from
males matching the age group represented in the study population
(20–45 years old, n=50, group 2). The serum samples were
rendered anonymous before testing for influenza antibodies. To
establish the contemporary prevalence of antibodies to A/
H1N1pdm, another group of serum samples from a similar
population, collected on September 2009 (n=50, group 3), was
Pandemic Influenza in a Military Ship: Serosurvey
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collected two months after the pandemic influenza peak in Italy
(February 2010, n=50, group 4), was selected.
All these samples were tested with HAI and CF assay, and an
antibody titer $1:10 in both HAI and CF assays was established as
a cut-off for seropositivity to influenza A/H1N1pdm. The results
obtained on these four sets of samples, shown in Table 1, support
the adequacy of the adopted criterion to retrospectively identify
the A/H1N1pdm infections.
Serological survey on the crew members
Serum samples from the study subjects were collected aboard on
September 6, 2010, just before the end of the cruise. A serum
sample was available for 216 of the 237 crew members; for 5
samples the results of serology were not interpretable because of
unspecific reaction in HAI test. Overall a positive serology was
found for 83 of the 211 crew member for whom a valid result was
available (39.3%). As shown in Table 2, the proportion of
individuals testing positive was higher among individual aged less
than 40 compared to older crewmen, although this difference was
not significant, while no difference was found according to rank.
No significant difference was found when comparing prevalence
recorded in specific living quarters or working areas, unless
considering their crowding. In fact, those persons who were in
living quarters with 1–2 persons were significantly less likely to test
positive when compared to the personnel of more crowded living
quarters, and a similar trend was found when considering the
number of persons in working areas (Table 2).
The proportion of positive results was similar in individuals who
received or did not receive seasonal influenza vaccination in the
previous year.
All the individuals who reported an ARI episode or suspected or
confirmed A/H1N1pdm influenza had available serology results.
Both individuals who fulfilled the surveillance case definition for
influenza tested positive, as did 4/7 (57.10%) individuals with two
episodes of ARI and 21/45 (46.7%) of individuals who reported a
single ARI episode (Table 3). Overall, the proportion of
individuals testing positive was higher among those who reported
ARI or suspected/confirmed A/H1N1pdm influenza (27/54,
50.0%) compared to those who did not (58/157, 36.9%) although
the difference was not statistically significant (p=0.12).
Figure 2 shows the distribution over time of ARI and suspected
or confirmed cases according to the results of serological tests. Cases
occurring in individuals who tested positive increased between
weeks 31 and 36. However, due to the short time lapse between the
last recorded episodes and the serum sampling time, it is reasonable
to expect that a significant proportion of individuals who could have
been infected after week 35 would result serologically negative.
It is noteworthy that, among the patients who tested
serologically positive to A/H1N1pdm, the first ARI appeared on
May 25, i.e. two days after the cruise start and two days before the
first stop of the ship (Beirut), in a patient who did not show any
subsequent ARI episode, suggesting that this first (possibly index)
case could have acquired the infection in Italy.
Discussion
It is well known that the serological response to the infection
with a given influenza subtype is influenced by the extent of cross-
reaction with heterologous subtypes, previous exposure to related
strains, individual variability and age. In addition, the measure of
antibody response is prone to variability due to the experimental
procedures, such as type of red blood cells or virus preparation.
Several studies have considered a HAI titer in the range of ,1:40
for their conclusions, as the scope was to establish the level of pre-
existing protective immunity, while only few studies reports lower
Figure 1. Distribution of cases according to the time of symptoms onset. Black bar: acute respiratory illness (ARI) episodes; gray bars:
episodes fulfilling suspected A/H1N1pdm case definition. The arrows indicate the arrival to the stopover port. Location of docking sites: Beirut,
Lebanon; Lymassol, Cyprus; Mersin, Turkey.
doi:10.1371/journal.pone.0015933.g001
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strains of influenza virus. Considering the protective threshold, in
Italy the pre-pandemic frequency of antibodies against A/
H1N1pdm in the general population is in the range of 6–7%
individuals aged 0–55 years, and increases to 22% in over 65 [17].
In UK, a protective titer has been detected in 9.8% of individuals
aged 25–49 [7], while 18.1% shows antibodies titered 1:8 in the
pre-pandemic era. In another study, conducted in Finland, 0.8%
of individuals aged 20–39 show protective antibodies, and 2.5%
showed titers of 1:10 [18]. The pre-pandemic prevalence of HAI
antibodies in military personnel was 15% with at 1:10 and 9.4% at
1:40 [14]. In residual hospital serum samples from persons aged
18–24 years the pre-pandemic seroprevalence (1:40) was 6% [19].
The aim of the present study was to establish retrospectively the
rate of infection in a close community for which pre-infection
serum samples were not available. The combined serological
approach, based on the contemporary presence of HAI and of CF
antibodies at a titer $1:10, was established on the basis of a
preliminary analysis conducted in patients who seroconverted by
definition (infected patient’s population, group 1), and was
validated in three sentinel groups, representing, respectively, age
matched male individuals sampled before the pandemic (group 2),
at the time of the cruise end (group 3) and after the 2009 pandemic
influenza wave (group 4). In fact, the low HAI titer threshold
allowed us to maximize the sensitivity, and the contemporary
presence of CF was used to increase the specificity of our infection
Table 1. Proportion of serum samples with contemporary HAI and CF titers $1:10 in 4 control groups.
Time of collection Frequency of individuals showing both HAI and CF titers $1:10
Group 1
(A/H1N1pdm-infected patients)
T0 0%
T1 85.7%
Group 2 September 2008 10.2%
Group 3 September 2009 8.2%
Group 4 February 2010 37.7%
Group 1: T0 and T1: paired acute and convalescent serum samples from patients with A/H1N1pdm infection confirmed by RT-PCR.
Group 2: serum samples submitted to our laboratory for HIV antibody screening and resulted HIV-negative in September 2008, from males matching the age group
represented in the study population.
Group 3: serum samples submitted to our laboratory for HIV antibody screening and resulted HIV-negative in September 2009, from males matching the age group
represented in the study population.
Group 4: serum samples submitted to our laboratory for HIV antibody screening and resulted HIV-negative, 2 months after the pandemic influenza peak in Italy
(February 2010).
doi:10.1371/journal.pone.0015933.t001
Table 2. Results of influenza A/H1N1pdm serology in 211 crew members of the Italian military ship Scirocco.
Characteristics Positive/total (%)
Odds Ratio
(95% confidence interval) p
Age
$40 years 10/34 (29.4) ref
30–39 years 30/71 (42.3) 1.76 (0.73 – 4.21) 0.27
20–29 years 43/106 (40.6) 1.64 (0.71–3.77) 0.24
Rank
Commissioned officers 14/29 (48.3) ref
Warrant officers 32/84 (38.1) 1.54 (0.67 – 3.55) 0.31
Petty officers/enlisted personnel 37/98 (37.8) 1.01 (0.56 – 1.85) 0.96
Number of persons in living quarter
1–2 5/27 (18.5) ref
3–9 16/35 (45.7) 3.70 (1.14–12.02) 0.03
$10 62/149 (41.6) 3.17 (1.13– 8.73) 0.03
Number of persons in working area
1–5 7/28 (25.0) ref
6–10 20/48 (41.7) 2.14 (0.76 – 6.0) 0.14
.10 56/135 (41.5) 2.13 (0.85 – 5.34) 0.11
Previous seasonal influenza vaccination
Yes 37/96 (38.5) ref
No 46/115 (40.0) 1.06 (0.61–1.85) 0.83
doi:10.1371/journal.pone.0015933.t002
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indicator of recent infection [20–21].
On the whole, the data obtained on a representative adult
population matching the demographical characteristics of our
study population indicates that, indeed, the rate of serological
positivity against A/H1N1pdm in the pre-pandemic era is about
10%, confirming previous literature data.
In the time frame overlapping with that considered in the study,
thisproportiondonotsignificantlyincreaseinthecontrolpopulation.
Thus, assuming a similar background of 10% of seropositivity in
the study population, we may infer that about 30% of the sailors
actually had acquired the infection during the cruise. The
association of the positivity rate with crowding of living quarters
supports this hypothesis.
This estimate is in keeping with that from a study conducted in
military personnel from Singapore (29.4%), based on seroconver-
sion rate over a 3 months period during 2009 [14].
In the Scirocco ship, only two of the seropositives showed
clinical signs consistent with the case definition, while about half
showed mild symptoms and the remaining half remained fully
asymptomatic during the cruise.
These results are in apparent contradiction with those from
other shipborne outbreaks, where higher proportion of febrile
infections has been reported [10–13]. The reasons for such
differences are unclear, although some discrepancies in clinical
surveillance systems may be at least in part accounting for.
Nevertheless, our results suggest that the introduction influenza A/
H1N1pdm in a close community may result in a small number of
clinically relevant diseases in spite of a wide spread, detected by
serological investigation.
Our data also suggest that previous vaccination against seasonal
viruses was not protective against A/H1N1pdm infection, in
agreement with previous reports performed in similar settings [11,13].
The present study presents some limitation. First, pre-pandemic
serum samples of the crewmen were not available; therefore our
estimate of the baseline seroprevalence is only speculative, leading
to a possibly imprecise estimate of proportion of peoples who
contracted the infection during the cruise. Second, according to
the surveillance protocol, afebrile or low grade fever cases were not
tested by PCR, so it is not possible to demonstrate that cases
occurring in patients who tested seropositive at the end of cruise
were actually attributable to influenza A/H\N1pdm infection.
The results of the present study may be relevant for planning
public health strategies in the context of early pandemic. In fact,
clinical surveillancecriteria established duringthe early phases of an
evolving pandemic may prove inadequate to monitor the actual
spread and the severity of the phenomenon, and need timely update
to provide a realistic estimate. In this context, serosurveillance data,
particularly from semi-closed communities, may be crucial in order
to timely define the real spectrum of clinical presentation and the
possible public health impact, essential to identify and implement
adequate control measures. As final consideration, biorepositories
may represent a valuable resource to help define the pre-pandemic
population immunity and to monitor the changes in the sero-
prevalence, providing unbiased collection of samples supplied with
demographic, epidemiological and clinical information.
Materials and Methods
Source of samples
Crew members. The study was performed among 216 crew
members of the Italian military ship Scirocco. A sample of about 5 ml
Table 3. Results of influenza A/H1N1pdm serology in 211
crew members of the Italian military ship Scirocco, according
to respiratory illness reported during the cruise.
Type of illness Positive/total (%)
Confirmed/suspected influenza A/H1N1pdm 2/2 (100)
Acute respiratory illness (1 Episode) 21/45 (46.7)
Acute respiratory illness (.1 Episode) 4/7 (57.1)
No acute respiratory illness 58/157 (36.9)
doi:10.1371/journal.pone.0015933.t003
Figure 2. Distribution of acute respiratory illness (ARI) and suspected A/H1N1pdm cases, according to the time of symptoms onset
and to the results of Influenza A/H1N1pdm-specific serological tests. Black bars: seropositives; gray bars: seronegatives.
doi:10.1371/journal.pone.0015933.g002
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personnel left the ship. The study has been approved by the Ethics
Committee of the National Institute for Infectious Diseases ‘‘L.
Spallanzani’’. All study participants provided written informed consent.
Virus stock preparation
A/H1N1pdm influenza virus (kindly provided by Prof. A. Azzi,
Florence, Italy) wasamplified on Madin-Darby Canine Kidney cells
geneticallymodifiedto over-express a-2,6-linkedsialicacid (MDCK
SIAT1, kindly provided by F. Baldanti, Pavia, Italy) in Dulbecco’s-
modified-Eagle’s medium (D-MEM) containing 2 mg/ml of TPCK-
treated trypsin (SIGMA) at 35uC in a 5% CO2 humidified
atmosphere. The MDCK SIAT1 cell line has been previously
described [22]. The haemagglutination titer of the virus stock was
determined using group 0 fresh human blood red cells according to
the WHO protocol [23].
The virus was inactivated by exposing to UV lights for 109 and
stored at –80uC until use. Complete inactivation of UV-exposed
virus was checked by infecting MDCK SIAT1 monolayers with
undiluted preparation and by back titrating the infectivity after 5
days of incubation.
Serologic tests
To retrospectively identify the A/H1N1pdm infections, the
antibody titer established by Haemagglutination Inhibition (HAI)
and Complement Fixation (CF) assays was determined. The
choice of performing in parallel FC and HAI assay was motivated
by the transient expression of the fixing complement antibodies,
which renders the test more useful in studies of recent infections
[20–21], and may partially correct the seroprevalence values
estimated on the basis of HAI, that shows a variable extent of
background positivity [7]. As challenge in both assays an UV-
inactivated influenza A/H1N1pdm virus preparation was used.
HAI assays were performed in V-bottom 96-well plates using
group 0 fresh human blood red cells [23]. All specimens were
tested in serial twofold dilutions (from 1:10 up to 1:320). CF test
was done by a standard Kolmer microthecnique [20] using the
same inactivated virus preparation. Standard reagents for the
development of the CF reaction were from commercial source
(Institut Virion/Serion GmbH, Germany). Serial serum dilutions
(1:10 up to 1:80) were tested. Negative and high-positive controls
were included in each run of HAI and CF tests.
For computational purpose, a value of 1:5 was assigned to the
samples resulting CF- or HAI-negative at 1:10.
The reciprocal of the dilutions of the HAI and CF were
transformed to log2 for statistical evaluation.
Biosafety Laboratory Facilities
All experiments with live A/H1N1pdm were conducted by
using Biosafety Level 3-plus (BSL3+) containment procedures
[24]. All the investigators were required to wear appropriate masks
with HEPA filters.
Statistical analysis
Standard univariate methods were used to assess the association
between individuals’ characteristics and serology results.
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